Lilly’s Zepbound is a dual glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide 1 (GLP-1) receptor agonist while Novo’s Wegovy is a GLP-1 receptor agonist.
Outlook’s Lytenava is a recombinant monoclonal antibody that binds and blocks vascular endothelial growth factor (VEGF) thereby reducing endothelial cell proliferation, vascular leakage, and new
Veeva’s VP of global medical, Christoph Bug, stated that Veeva has also invested in medical affairs. Image credit: Veeva. Pharmaceutical companies are always looking to
Kronos has downsized twice in the past year, firing 19% of its staff in November 2023 and then a further 21% in March 2024. Image
Syros noted that SELCT-MDS-1 Phase III trial’s failure to meet its endpoint constituted a default event under its secured loan facility with Oxford Finance. Image
Neurotech’s NT-501 implant contains allogeneic retinal pigment epithelium (RPE) cells that produce therapeutic proteins and ciliary neurotrophic factor (CNTF) for targeted and continuous treatment. Image
Tezspire is a thymic stromal lymphopoietin (TSLP) inhibiting monoclonal antibody, which generated $86m in sales in 2023. Image credit: eamesBot / Shutterstock. AstraZeneca and Amgen
DBV reported cash reserves of $46.4m as of 30 September, down by $92.2m it had at the end of last year. Image credit: UncleFredDesign /
Intra-Cellular expects Caplyta to rake in about $665-685m in sales this year. Image credit: Lightspring / Shutterstock. Having raised the full-year sales guidance for Caplyta
The merged company plans to focus on NLS’s Dual Orexin Agonist (DOA) platform and Kadimastem’s allogenic cell therapy program. Image credit: Lightspring / Shutterstock. Switzerland-based